SymbioCellTech Wins ADA Innovation Challenge for Groundbreaking Diabetes Biotherapy

The American Diabetes Association® (ADA) announced the winners of its prestigious Innovation Challenge competition. Innovators from across the globe presented groundbreaking ideas aimed at transforming diabetes care before a distinguished panel of potential funders and an audience of professionals in the field. The objective was clear: to advance transformative solutions for people living with diabetes, their families, and caregivers. Among the three winners selected from five finalists presenting at the ADA’s 84th Scientific Sessions, SymbioCellTech emerged as a winner in the challenge.

SymbioCellTech’s innovative biotherapy for patients with type 1 diabetes stands out for its unique approach that eliminates the need for encapsulation devices or antirejection drugs. This remarkable advancement promises to significantly improve the quality of life and is recognized as a highly anticipated therapeutic to take into human trails.

About the American Diabetes Association’s Scientific Sessions 
The ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Orlando, FL on June 21-24. More than 11,000 leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADAScientificSessions.